Asset Management One Co. Ltd. Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Asset Management One Co. Ltd. raised its position in Hologic, Inc. (NASDAQ:HOLX) by 58.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 145,028 shares of the medical equipment provider’s stock after acquiring an additional 53,762 shares during the period. Asset Management One Co. Ltd. owned approximately 0.06% of Hologic worth $10,529,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. General Partner Inc. acquired a new stake in Hologic in the fourth quarter valued at about $26,000. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Cromwell Holdings LLC lifted its holdings in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares during the period. Covestor Ltd lifted its holdings in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the period. Finally, Loomis Sayles & Co. L P lifted its holdings in Hologic by 29.3% in the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 183 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent analyst reports. Jefferies Financial Group initiated coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price for the company. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Wolfe Research initiated coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $85.77.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is owned by insiders.

Hologic Price Performance

Hologic stock opened at $63.24 on Monday. Hologic, Inc. has a 52-week low of $62.94 and a 52-week high of $84.67. The firm has a market capitalization of $14.27 billion, a P/E ratio of 19.95, a PEG ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average of $71.04 and a 200-day moving average of $77.19.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.